News | October 21, 2023
Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Increased capability to produce medicines for challenging diseases including cancer
Lokavant provides clinical trial intelligence
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Commenced operations in flood-affected Himachal Pradesh
Subscribe To Our Newsletter & Stay Updated
